Gemcitabine in Combination With Cisplatin as Neoadjuvant NSCLC Chemotherapy

Gemcitabine Plus Cisplatin as Neoadjuvant Chemotherapy in Operable Non Small Cell Lung Cancer

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00191841

Enrollment

Registered

2005-09-19

Start date

2002-12-31

Completion date

2006-02-28

Last updated

2006-07-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Carcinoma, Non-Small-Cell Lung

Brief summary

To evaluate the clinical response rate of neoadjuvant chemotherapy with gemcitabine and cisplatin in patients with operable NSCLC

Interventions

DRUGgemcitabine

DRUGCisplatin

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* histologic or cytologic diagnosis of operable non-small cell lung cancer (IB-IIIA) * no prior chemotherapy * WHO criteria for disease status assessment

Exclusion criteria

* Concurrent administration of any other tumor therapy * pregnant or breast feeding * serious concomitant disorders

Design outcomes

Primary

Measure	Time frame
Antitumor activity	—

Secondary

Measure	Time frame
Duration of response, time to progressive disease, time to treatment failure	—

Countries

Russia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026